Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JQ-1,Molibresib,Venetoclax
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
UNH Researchers Discover New Inhibitor Drug Combination for Rare Form of Cancer
Details : Researchers at the University found that adding venetoclax or panabinostat to the inhibitors was more effective than adding ibrutinib—with panobinostat offering the greatest combination therapy.
Brand Name : JQ-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 14, 2021
Lead Product(s) : JQ-1,Molibresib,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?